Neon Therapeutics, Inc. (NTGN) financial statements (2020 and earlier)

Company profile

Business Address 40 ERIE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29103
Cash and cash equivalents2953
Short-term investments 51
Other undisclosed current assets22
Total current assets:31105
Noncurrent Assets
Operating lease, right-of-use asset8
Property, plant and equipment78
Other noncurrent assets00
Total noncurrent assets:159
TOTAL ASSETS:46114
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities913
Accounts payable24
Accrued liabilities78
Debt1 
Total current liabilities:1013
Noncurrent Liabilities
Long-term debt and lease obligation7 
Operating lease, liability7
Liabilities, other than long-term debt00
Other liabilities00
Total noncurrent liabilities:70
Total liabilities:1713
Stockholders' equity
Stockholders' equity attributable to parent29101
Common stock00
Additional paid in capital283275
Accumulated other comprehensive loss (0)
Accumulated deficit(254)(174)
Total stockholders' equity:29101
TOTAL LIABILITIES AND EQUITY:46114

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Operating expenses(81)(79)
Operating loss:(81)(79)
Nonoperating income
(Other Nonoperating income)
12
Net loss attributable to parent:(80)(77)
Preferred stock dividends and other adjustments (6)
Net loss available to common stockholders, diluted:(80)(83)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(80)(77)
Comprehensive loss:(80)(77)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)
Comprehensive loss, net of tax, attributable to parent:(80)(77)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: